Dianthus Therapeutics

Yahoo Finance • 6 days ago

Plus Therapeutics (PSTV) Soars 40% as Firm Seals Partnership with United Healthcare

We recently published Massive Gains: 10 Stocks Investors Can’t Stop Buying. Plus Therapeutics Inc. (NASDAQ:PSTV) is one of the top performers on Thursday. Shares of Plus Therapeutics soared by 39.29 percent on Thursday to finish at $0.563... Full story

Yahoo Finance • 17 days ago

Implied XBI Analyst Target Price: $142

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 19 days ago

Notable Friday Option Activity: GLW, DNTH, CROX

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Corning Inc (Symbol: GLW), where a total volume of 46,563 contracts has been traded thus far today, a contract volume whi... Full story

Yahoo Finance • 20 days ago

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEW YORK and WALTHAM, Mass., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat se... Full story

Yahoo Finance • 22 days ago

Dianthus Therapeutics prices upsized $251M securities offering

Dianthus Therapeutics (NASDAQ:DNTH [https://seekingalpha.com/symbol/DNTH]) has priced [https://seekingalpha.com/pr/20227263-dianthus-therapeutics-inc-announces-pricing-of-upsized-251-million-underwritten-public] its recently announced and... Full story

Yahoo Finance • 22 days ago

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

NEW YORK and WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat se... Full story

Yahoo Finance • 22 days ago

Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential

We recently published 10 Stocks With Eye-Popping Gains; 7 Soar to Fresh Highs. Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is one of the top performers on Monday. Dianthus Therapeutics soared to a new record high on Monday, as investors che... Full story

Yahoo Finance • 23 days ago

Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering

NEW YORK and WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat se... Full story

Yahoo Finance • 24 days ago

Top movers in Monday's pre-market session

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMMENT HOUR [https://www.ch... Full story

Yahoo Finance • 24 days ago

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat se... Full story

Yahoo Finance • 3 months ago

Stifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% Upside

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is among the best small company stocks to invest in. Stifel reaffirmed a Buy rating on Dianthus Therapeutics, Inc. (NASDAQ:DNTH) while maintaining a price target of $52.00, citing the strength of t... Full story

Yahoo Finance • 3 months ago

Climb Bio appoints Cindy Driscoll as SVP Finance and principal financial officer

Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotech company with a market capitalization of $81 million, announced the appointment of Cindy Driscoll as Senior Vice President, Finance, effective June 17, 2025. According to InvestingPro... Full story

Yahoo Finance • 4 months ago

Dianthus Therapeutics stock maintains buy rating ahead of September trial data

Stifel reiterated a buy rating and $52.00 price target on Dianthus Therapeutics (NASDAQ:DNTH), representing significant upside from the current price of $18.22. According to InvestingPro data, analyst targets range from $34 to $84, with th... Full story

Yahoo Finance • 4 months ago

Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference

NEW YORK and WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat seve... Full story

Yahoo Finance • 4 months ago

Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors

Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisiti... Full story

Yahoo Finance • 5 months ago

Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September

MaGic trial exceeded enrollment target of 60 patients Top-line results anticipated this September will be the first of three DNTH103 catalysts by YE'26 Building a neuromuscular franchise with DNTH103 in gMG, CIDP and MMN with a potential... Full story

Yahoo Finance • 7 months ago

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results

Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder a... Full story

Yahoo Finance • 7 months ago

Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors

Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion Mr. King also led the commercial strategy behin... Full story

Yahoo Finance • 7 months ago

Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences

NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat sev... Full story

Yahoo Finance • 8 months ago

Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences

NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat sev... Full story